Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy.
Exp Oncol
; 34(4): 367-9, 2012 Dec.
Article
em En
| MEDLINE
| ID: mdl-23302998
ABSTRACT
AIM:
Methotrexate (MTX) is an antifolate agent that acts inhibiting purine and pyrimidine synthesis. The objective of the study was to evaluate the viability of Hep-2 human laryngeal cancer cells to the treatment with MTX chemotherapy in vitro.METHODS:
Cultured Hep-2 cells were treated with 0.25, 25.0 and 75 µM MTX for 24 h, and their viability was evaluated with Bcl-2-FITC antibody in flow cytometry.RESULTS:
The numbers of viable Hep-2 cells after 24 h treatment with 0.25, 25.0 and 75.0 uM MTX were 85.43%, 22.46% and 8.42%, respectively (p < 0.05). Therefore, MTX possesses a dose-dependent effect on viability of Hep-2 cells in vitro.CONCLUSION:
The highest MTX concentration is associated with highest tumor cell sensitivity of human laryngeal cancer cells of Hep-2 line.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Escamosas
/
Sobrevivência Celular
/
Neoplasias Laríngeas
/
Metotrexato
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
Idioma:
En
Revista:
Exp Oncol
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Brasil